Gilles Freyer

6PUBLICATIONS
43CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|Jun 04, 2024
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Gilles Freyer, Anne Floquet, Olivier Tredan

|May 31, 2024
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.

Pauline Corbaux, Gilles Freyer, Olivier Glehen

|Mar 05, 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Gilles Freyer, Anne Floquet, Olivier Tredan

|Feb 16, 2024
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.

Aurore Carrot, Stéphane Oudard, Olivier Colomban

|Jan 12, 2024
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".

Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa

Pageof 1

Frequent Collaborators

3 joint publications

Benoit You

2 joint publications

Olivier Colomban

2 joint publications

Michele Lamuraglia

2 joint publications

Michel Fabbro